Joana Goncalves - 17 Aug 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Reporting relationship: Chief Medical Officer
Issuer ticker: ORKA
Reported as of: 17 Aug 2026
Net transaction value: -$782,882
SEC form: 4
Accepted by SEC: 17 Aug 2026, 18:09:40 UTC
Prior SEC filing: 15 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves

Key filing fact

Joana Goncalves filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 17 Aug 2026.

Key facts

This page summarizes Joana Goncalves's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
8 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Aug 2026, 18:09.

Change

Previous filing in this sequence was filed on 15 Jul 2026.
Current net transaction value: -$782,882.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001756991 Primary reporting owner

Goncalves Joana

Relationship: Chief Medical Officer
Address: C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
Signature: /s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORKA transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,500
Change %: +11%
Price: $6.84^*
Shares after: 36,218
Date: 17 Aug 2026
Ownership: Direct

ORKA transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,500
Change %: +9.7%
Price: $7.80^*
Shares after: 39,718
Date: 17 Aug 2026
Ownership: Direct

ORKA transaction

Common Stock

Sale

Transaction value: $98,687
Shares: -900
Change %: -2.3%
Price: $109.65
Shares after: 38,818
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ORKA transaction

Common Stock

Sale

Transaction value: $33,155
Shares: -300
Change %: -0.77%
Price: $110.52
Shares after: 38,518
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F3

ORKA transaction

Common Stock

Sale

Transaction value: $371,886
Shares: -3,320
Change %: -8.6%
Price: $112.01
Shares after: 35,198
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F4

ORKA transaction

Common Stock

Sale

Transaction value: $279,154
Shares: -2,480
Change %: -7%
Price: $112.56
Shares after: 32,718
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORKA transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -3,500
Change %: -1.7%
Price: $0.000000^*
Shares after: 197,063
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,500
Exercise price: $6.84
Footnotes: F6

ORKA transaction Derivative

Employee Warrant (right to buy)

Options Exercise

Transaction value
Shares: -3,500
Change %: -2%
Price: $0.000000^*
Shares after: 168,492
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,500
Exercise price: $7.80
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.04, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.27 to $111.00, inclusive.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.34 to $112.33, inclusive.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $112.86, inclusive.

Footnote F6

The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

Footnote F7

The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.